TerminatedPhase 2NCT03606174
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Studying Upper tract urothelial carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mirati Therapeutics Inc.
- Principal Investigator
- Hirak Der-Torossian, MD, M.D. Ph.DMirati Therapeutics Inc.
- Intervention
- Sitravatinib(drug)
- Enrollment
- 260 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2022
Study locations (30)
- The University of Arizona Cancer Center, Tucson, Arizona, United States
- University of California Irvine, Irvine, California, United States
- Rocky Mountain Cancer Centers, Aurora, Colorado, United States
- Yale School of Medicine, New Haven, Connecticut, United States
- SCRI - Florida Cancer Specialists- North Region, St. Petersburg, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- SCRI - Florida Cancer Specialists - West Palm Beach, West Palm Beach, Florida, United States
- The University of Chicago, Chicago, Illinois, United States
- Indiana University - Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
- Norton Cancer Institute - Broadway, Louisville, Kentucky, United States
- Ochsner Cancer Institute, New Orleans, Louisiana, United States
- Maryland Oncology Hematology, P.A., Lanham, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
- Washington University School of Medicine - Siteman Cancer Center, St Louis, Missouri, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03606174 on ClinicalTrials.govOther trials for Upper tract urothelial carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07452432Korean Prospective Upper Tract Urothelial Carcinoma CohortSamsung Medical Center
- RECRUITINGNANCT07321210Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC): A Randomized Clinical TrialTianjin Medical University Second Hospital
- RECRUITINGPHASE2NCT07265947Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaTyra Biosciences, Inc
- RECRUITINGPHASE2NCT07225374Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUCSamsung Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT07492225Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized TrialChanghai Hospital
- RECRUITINGPHASE2NCT06356155Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial CancerUniversity of Michigan Rogel Cancer Center
- RECRUITINGPHASE2NCT07126119Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUCTianjin Medical University Second Hospital
- RECRUITINGPHASE1NCT06848868Ambulatory Flexible URS for UTUC SurveillanceChinese University of Hong Kong